Recent Finacing
Recent Raise
EraCal, a spinoff of University of Zurich and Harvard, develops Era-107, an oral selective appetite suppressor from its proprietary discovery platform, now entering preclinical studies and expanding to other indications.
Focus Areas
Recent Investors
Funding round
Investors
See the team members at EraCal.
